CD274 and neoplasm: Durvalumab, a drug that blocks interaction of PD-1 and PD-L1, was included on the basis of preclinical data suggesting that the use of an anti-PD-L1 therapy with IPH5401 would reduce tumor growth, delay tumor progression, and improve overall efficacy101.